主题：国医药和辉瑞的谈判崩了 -- 花童
BOSTON – The antiviral drug nirmatrelvir plus ritonavir (Paxlovid) was granted Emergency Use Authorization for treating COVID-19 in December 2021. In clinical trials, the antiviral was associated with an 88% reduction in hospitalization or death among high-risk, unvaccinated individuals with COVID-19.
https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/paxlovid-effective-in-reducing-covid-19-hospitalization
- 相关回复 上下关系8
压缩 3 层
🙂按米国CDC报道是降低51%，不是降低5倍。 5 戒定慧 字45 2023-01-10 01:34:57
🙂打疫苗和不打疫苗 1 Swell 字148 2023-01-10 16:46:20
🙂降低？有效？ 桥上 字0 2023-01-10 23:18:23
🙂请看原文吧
🙂辉瑞不敢做打了疫苗人群的临床试验，实际应该是效果很差 2 混沌之源 字333 2023-01-16 03:38:58
🙂这个不太对 8 Swell 字412 2023-01-16 14:52:34
🙂香港大學: 輝瑞病徵後5日內口服藥死亡率減66% 3 脊梁硬 字1559 2023-01-11 19:13:37
🙂其实我还看到过一个数据。 5 花童 字341 2023-01-10 04:44:23